Summary
Post-herpetic neuralgia (PHN) following acute shingles caused by the herpes simplex virus is a painful and often disabling condition. Treatment of the condition can involve a range of drug therapies. In addition, patients with continuing pain may make several visits to general practitioners and hospital outpatient departments. The costs of treatment for these patients may be substantial.
The main objective of this study was to estimate the costs and consequences to the UK National Health Service (NHS) of the treatment of PHN following shingles, and the effect of the condition on patients’ lives in terms of pain and time off usual activities such as work. The lifetime direct treatment costs of a cohort of people from onset of PHN to resolution of the disease or death were calculated. These costs were estimated from data on the type and quantity of health resources used, and the unit costs or prices of those resources.
This study has shown that PHN can be a costly consequence of acute shingles. For patients attending a tertiary referral centre the lifetime cost was £770. For a 1-year incidence cohort of people with shingles in the UK, the lifetime costs of treating PHN are between £4.8 million (incidence of 21 000 people) and £17.9 million (incidence of 78 200 people).
Efforts are needed to reduce the incidence or severity of PHN. If antiviral therapy can be shown to reduce this incidence, the costs estimated in this study should form part of the overall cost-benefit equation for the treatment of acute shingles.
Similar content being viewed by others
References
Watson CPN, Morshead C, van de Kooy D, et al. Post herpetic neuralgia: post-mortem analysis of a case. Pain 1988; 34: 129–38
Watson CPN, Deck JH, Morshead C, et al. Post herpetic neuralgia: further post-mortem studies of cases with and without pain. Pain 1991; 44: 105–17
Bowsher D. Acute herpes zoster and postherpetic neuralgia: effects of acyclovir and outcome of treatment with amitriptyline. Br J Gen Pract 1992; 42: 244–6
Bowsher D. The effects of acyclovir therapy for herpes zoster on treatment outcome in post herpetic neuralgia: a randomised study. Eur J Pain 1994; 15: 9–12
Cossins L. Features of commonest diagnoses in 1017 successive pain clinic cases. Pain 1990; 5 Suppl.: S350
Hartunian NS, Smart CN, Thompson MS. The incidence and economic costs of cancer, motor vehicle injuries, coronary heart disease and stroke: a comparative analysis. Am J Public Health 1980; 70: 1249–60
Crosse B. Efficacy and cost of the drugs used in shingles. Prescriber 1992: 103–10
Fenn P, McGuire A, Phillips V, et al. The analysis of censored treatment cost data in economic evaluation. Oxford Centre for Health Economics Research 1993; discussion paper 93.1
Review Body on Doctors and Dentists Remuneration. Twenty First Report; Cm 1412. London: Her Majesty’s Stationery Office, 1991
Office of Health Economics. Compendium of Health Statistics, 7th ed. London: Office of Health Economics, 1989
Davies LM. Community care: the costs and quality. Health Services Management Research 1988; 1(3): 145–55
Review Body for Nursing Staff, Midwives, Health Visitors and Professions Allied to Medicine. 8th Report on Nursing Staff, Midwives and Health Visitors; Cm 1410. London: Her Majesty’s Stationery Office, 1991a
Review Body for Nursing Staff, Midwives, Health Visitors and Professions Allied to Medicine. 8th Report on Professions Allied to Medicine 1991. Cm 1411. London: Her Majesty’s Stationery Office, 1991b
Chartered Institute of Public Finance Accountanct 1990. The Health Database. Health Service Trends. Vol 1. London: Healthcare Financial Management Association, 1990
Monthly Index of Medical Specialties. Haymarket Medical Ltd: London, October 1991
National Association of Health Authorities. NHS Economic Review. Birmingham: National Association of Health Authorities, 1990
National Association of Health Authorities and Trusts. The autumn 1990 survey: a survey of district health authorities financial position. Birmingham: National Association of Health Authorities and Trusts, 1991
Kurtzke JF. Neuroepidemiology. Annals of Neurology 1984; 16: 265–77
Central Statistical Office. Annual Abstract of Statistics. Her Majesty’s Stationery Office, 1992
Watson CPN, Watt VR, Chipman M, et al. The prognosis with postherpetic neuralgia. Pain 1991b; 46: 195–9
Watson CPN, editor. The medical treatment of post herpetic neuralgia: antidepressants, other therapies, and practical guidelines for management. In: Herpes zoster and post herpetic neuralgia. Pain research and clinical management. Amsterdam: Elsevier, 1993; 8: 205–20
Straus SE. Shingles: sorrows, salves, solutions. JAMA 1993; 269(14): 1836–9
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Davies, L., Cossins, L., Bowsher, D. et al. The Cost of Treatment for Post-Herpetic Neuralgia in the UK. Pharmacoeconomics 6, 142–148 (1994). https://doi.org/10.2165/00019053-199406020-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199406020-00006